X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BGB 324 (bemcentinib) is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase (AXL). It is being evaluated for the treatment of STK11 mutated Non-Small Lung Cancer.
Lead Product(s): Bemcentinib,Pembrolizumab,Pemetrexed
Therapeutic Area: Oncology Product Name: BGB 324
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
BGB324 (bemcentinib) is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase (AXL). It is being evaluated in preclinical trials for the treatment of infection caused by Respiratory Syncytial Virus.
Lead Product(s): Bemcentinib
Therapeutic Area: Infections and Infectious Diseases Product Name: BGB324
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
BGB324 (bemcentinib) is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase (AXL) a promising therapeutic target for serious diseases. It is being developed for the treament of NSCLC.
Lead Product(s): Bemcentinib,Pembrolizumab,Pemetrexed
Therapeutic Area: Oncology Product Name: BGB324
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
BGB324 (bemcentinib) is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase (AXL) a promising therapeutic target for serious diseases. It is being investigated for non-small cell lung cancer (NSCLC).
Lead Product(s): Bemcentinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: BGB324
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
The facility will enable BerGenBio to continue its previously announced focused strategy of advancing its lead compound bemcentinib (BGB324) in 1st line Non-Small Cell Lung Cancer (NSCLC) and hospitalized COVID-19 patients.
Lead Product(s): Bemcentinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: BGB324
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Meteva AS
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 25, 2022
Details:
ADCT-601 (mipasetamab uzoptirine) is composed of a humanized monoclonal antibody that binds to human AXL (licensed from BerGenBio), conjugated using GlycoConnect™ technology (licensed from Synaffix BV) to a linker with a pyrrolobenzodiazepine (PBD)-dimer toxin.
Lead Product(s): Mipasetamab Uzoptirine,Gemcitabine
Therapeutic Area: Oncology Product Name: ADCT-601
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: ADC Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2022
Details:
Complete data analysis confirms that the primary endpoint of improved clinical response and key secondary endpoints were met in a subprotocol under the platform ACCORD2 study where bemcentinib was added to standard of care therapy.
Lead Product(s): Bemcentinib
Therapeutic Area: Infections and Infectious Diseases Product Name: BGB324
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
Pre-clinical NSCLC mouse models harboring STK11 mutations, sensitivity to PD-1 blockade was evaluated in the absence and presence of bemcentinib. Systemic inhibition of AXL with bemcentinib resulted in expansion of tumor-associated T cells and restored therapeutic response.
Lead Product(s): Bemcentinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: BGB324
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
In total, 179 eligible patients were enrolled across both studies between May 2020 and March 2021, randomly allocated on an open-label basis to treatment with bemcentinib in addition to standard of care (SoC) compared to SoC alone.
Lead Product(s): Bemcentinib
Therapeutic Area: Infections and Infectious Diseases Product Name: BGB324
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University Hospital Southampton
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2021
Details:
The data indicate that the combination of bemcentinib, a once-daily oral AXL-inhibitor and LDAC is efficacious and well tolerated in the elderly and unfit relapsed AML population.
Lead Product(s): Bemcentinib,Cytarabine
Therapeutic Area: Oncology Product Name: BGBC003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
